As a gynecologist, Dr. Bruce B. Lee of Monterey, California knew that women suffering from the debilitating symptoms of uterine fibroids had limited effective treatment options outside of a major invasive surgical procedure – a hysterectomy. In fact, today roughly half of the 600,000 hysterectomies performed annually in the U.S. are for the treatment of fibroids. So Dr. Lee devised a revolutionary new, minimally invasive, out-patient, laparoscopic procedure using radiofrequency (RF) ablation to treat fibroids.

The procedure enables gynecologists to shrink or eliminate fibroids, significantly reducing symptoms, while leaving the uterus undamaged and intact, thus offering women a less invasive, uterine sparing alternative to a hysterectomy. Dr. Lee conducted a pilot study of 58 patients and subsequently a prospective multi-center study of 110 patients was completed. The procedure was very effective in significantly reducing or eliminating bothersome symptoms, and allowed women a rapid return to normal activity. Importantly, the procedure also demonstrated an excellent safety profile.

In 2004, Dr. Lee co-founded Halt Medical, Inc. with CEO Jeffrey M. Cohen to develop, manufacture and commercialize the Acessa™ System for the treatment of symptomatic uterine fibroids without damaging or removing the uterus. In three multi-center clinical trials, more than 200 patients were successfully treated with Acessa. Heavy menstrual bleeding, pain, bloating and other debilitating fibroid symptoms were significantly reduced or eliminated, and quality of life was sharply improved. Since its commercial launch in 2012, Acessa has improved the lives of many women.

Acessa represents a significant advance in the treatment of symptomatic uterine fibroids, and has the potential to improve the lives of millions of women – without damaging or removing the uterus.

LI-00-0358-A